
HRMY Stock Forecast & Price Target
HRMY Analyst Ratings
Bulls say
Harmony Biosciences Holdings Inc. is projected to experience significant growth in WAKIX sales, with expectations to rise from approximately $160 million in 2020 to over $700 million by 2024, driven by the drug's safety and convenience advantages. The company’s promising pipeline includes multiple drug candidates, such as pitolisant in Phase 2 trials and the development of pitolisant-GR, which aims to enhance patient adherence by eliminating the need for dose titration. With a strong balance sheet to support both research and development and upcoming clinical trials, Harmony is positioned as a compelling growth story in the neurology sector.
Bears say
Harmony Biosciences Holdings Inc faces a negative outlook primarily due to the failure of its pivotal Phase 3 RECONNECT trial for ZYN002, which did not meet the primary endpoint, raising concerns about the effectiveness of the drug in treating Fragile X syndrome. Additionally, the company may encounter increased competition in the sodium oxybate market, which could hinder the growth of its leading product, Wakix, while a slowdown in new patient additions could further exacerbate this issue. Furthermore, uncertainties surrounding the success of ongoing clinical trials for various other candidates in its pipeline contribute to a bleak financial outlook for Harmony.
This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.
HRMY Analyst Forecast & Price Prediction
Start investing in HRMY
Order type
Buy in
Order amount
Est. shares
0 shares